Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

GRDN vs MCK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GRDN
Guardian Pharmacy Services, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$2.30B
5Y Perf.+116.0%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+52.2%

GRDN vs MCK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GRDN logoGRDN
MCK logoMCK
IndustryMedical - DistributionMedical - Distribution
Market Cap$2.30B$92.15B
Revenue (TTM)$1.46B$403.43B
Net Income (TTM)$53M$4.76B
Gross Margin20.2%3.6%
Operating Margin6.4%1.5%
Forward P/E29.6x19.3x
Total Debt$37M$7.39B
Cash & Equiv.$66M$5.69B

GRDN vs MCKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GRDN
MCK
StockSep 24May 26Return
Guardian Pharmacy S… (GRDN)100216.0+116.0%
McKesson Corporation (MCK)100152.2+52.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: GRDN vs MCK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: GRDN leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. McKesson Corporation is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
GRDN
Guardian Pharmacy Services, Inc.
The Growth Play

GRDN carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth 17.9%, EPS growth 144.1%, 3Y rev CAGR 16.8%
  • 17.9% revenue growth vs MCK's 16.2%
  • 3.6% margin vs MCK's 1.2%
Best for: growth exposure
MCK
McKesson Corporation
The Income Pick

MCK is the clearest fit if your priority is income & stability and long-term compounding.

  • Dividend streak 17 yrs, beta 0.04, yield 0.4%
  • 348.1% 10Y total return vs GRDN's 126.7%
  • Lower volatility, beta 0.04, current ratio 0.90x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthGRDN logoGRDN17.9% revenue growth vs MCK's 16.2%
ValueMCK logoMCKLower P/E (19.3x vs 29.6x), PEG 0.49 vs 1.58
Quality / MarginsGRDN logoGRDN3.6% margin vs MCK's 1.2%
Stability / SafetyMCK logoMCKBeta 0.04 vs GRDN's 1.04
DividendsMCK logoMCK0.4% yield; 17-year raise streak; the other pay no meaningful dividend
Momentum (1Y)GRDN logoGRDN+40.5% vs MCK's +4.6%
Efficiency (ROA)GRDN logoGRDN13.4% ROA vs MCK's 5.7%, ROIC 35.8% vs 5.4%

GRDN vs MCK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GRDNGuardian Pharmacy Services, Inc.
FY 2025
Corporate Segment
100.0%$1.4B
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B

GRDN vs MCK — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLGRDNLAGGINGMCK

Income & Cash Flow (Last 12 Months)

GRDN leads this category, winning 5 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 277.1x GRDN's $1.5B. Profitability is closely matched — net margins range from 3.6% (GRDN) to 1.2% (MCK). On growth, MCK holds the edge at +6.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…
RevenueTrailing 12 months$1.5B$403.4B
EBITDAEarnings before interest/tax$112M$6.8B
Net IncomeAfter-tax profit$53M$4.8B
Free Cash FlowCash after capex$70M$6.0B
Gross MarginGross profit ÷ Revenue+20.2%+3.6%
Operating MarginEBIT ÷ Revenue+6.4%+1.5%
Net MarginNet income ÷ Revenue+3.6%+1.2%
FCF MarginFCF ÷ Revenue+4.8%+1.5%
Rev. Growth (YoY)Latest quarter vs prior year+2.2%+6.0%
EPS Growth (YoY)Latest quarter vs prior year+40.0%+37.0%
GRDN leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

MCK leads this category, winning 6 of 6 comparable metrics.

At 29.2x trailing earnings, MCK trades at a 37% valuation discount to GRDN's 46.5x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs GRDN's 2.48x — a lower PEG means you pay less per unit of expected earnings growth.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…
Market CapShares × price$2.3B$92.1B
Enterprise ValueMkt cap + debt − cash$2.3B$93.8B
Trailing P/EPrice ÷ TTM EPS46.51x29.25x
Forward P/EPrice ÷ next-FY EPS est.29.62x19.28x
PEG RatioP/E ÷ EPS growth rate2.48x0.75x
EV / EBITDAEnterprise value multiple20.40x18.74x
Price / SalesMarket cap ÷ Revenue1.59x0.26x
Price / BookPrice ÷ Book value/share10.54x
Price / FCFMarket cap ÷ FCF28.47x17.63x
MCK leads this category, winning 6 of 6 comparable metrics.

Profitability & Efficiency

GRDN leads this category, winning 5 of 7 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $25 for GRDN.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…
ROE (TTM)Return on equity+25.4%+3.0%
ROA (TTM)Return on assets+13.4%+5.7%
ROICReturn on invested capital+35.8%+5.4%
ROCEReturn on capital employed+41.5%+30.5%
Piotroski ScoreFundamental quality 0–966
Debt / EquityFinancial leverage0.17x
Net DebtTotal debt minus cash-$28M$1.7B
Cash & Equiv.Liquid assets$66M$5.7B
Total DebtShort + long-term debt$37M$7.4B
Interest CoverageEBIT ÷ Interest expense129.16x33.79x
GRDN leads this category, winning 5 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

GRDN leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $22,675 for GRDN. Over the past 12 months, GRDN leads with a +40.5% total return vs MCK's +4.6%. The 3-year compound annual growth rate (CAGR) favors GRDN at 31.4% vs MCK's 27.3% — a key indicator of consistent wealth creation.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…
YTD ReturnYear-to-date+22.9%-8.5%
1-Year ReturnPast 12 months+40.5%+4.6%
3-Year ReturnCumulative with dividends+126.7%+106.4%
5-Year ReturnCumulative with dividends+126.8%+286.9%
10-Year ReturnCumulative with dividends+126.7%+348.1%
CAGR (3Y)Annualised 3-year return+31.4%+27.3%
GRDN leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — GRDN and MCK each lead in 1 of 2 comparable metrics.

MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than GRDN's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GRDN currently trades 87.7% from its 52-week high vs MCK's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…
Beta (5Y)Sensitivity to S&P 5001.04x0.04x
52-Week HighHighest price in past year$41.36$999.00
52-Week LowLowest price in past year$19.17$637.00
% of 52W HighCurrent price vs 52-week peak+87.7%+75.3%
RSI (14)Momentum oscillator 0–10047.416.2
Avg Volume (50D)Average daily shares traded461K757K
Evenly matched — GRDN and MCK each lead in 1 of 2 comparable metrics.

Analyst Outlook

MCK leads this category, winning 1 of 1 comparable metric.

Wall Street rates GRDN as "Buy" and MCK as "Buy". Consensus price targets imply 33.8% upside for MCK (target: $1007) vs 4.7% for GRDN (target: $38). MCK is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.

MetricGRDN logoGRDNGuardian Pharmacy…MCK logoMCKMcKesson Corporat…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$38.00$1006.50
# AnalystsCovering analysts331
Dividend YieldAnnual dividend ÷ price+0.4%
Dividend StreakConsecutive years of raises017
Dividend / ShareAnnual DPS$2.69
Buyback YieldShare repurchases ÷ mkt cap+1.3%+3.4%
MCK leads this category, winning 1 of 1 comparable metric.
Key Takeaway

GRDN leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MCK leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallGuardian Pharmacy Services,… (GRDN)Leads 3 of 6 categories
Loading custom metrics...

GRDN vs MCK: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is GRDN or MCK a better buy right now?

For growth investors, Guardian Pharmacy Services, Inc.

(GRDN) is the stronger pick with 17. 9% revenue growth year-over-year, versus 16. 2% for McKesson Corporation (MCK). McKesson Corporation (MCK) offers the better valuation at 29. 2x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate Guardian Pharmacy Services, Inc. (GRDN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — GRDN or MCK?

On trailing P/E, McKesson Corporation (MCK) is the cheapest at 29.

2x versus Guardian Pharmacy Services, Inc. at 46. 5x. On forward P/E, McKesson Corporation is actually cheaper at 19. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Guardian Pharmacy Services, Inc. 's 1. 58x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — GRDN or MCK?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to +126. 8% for Guardian Pharmacy Services, Inc. (GRDN). Over 10 years, the gap is even starker: MCK returned +348. 1% versus GRDN's +126. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — GRDN or MCK?

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Guardian Pharmacy Services, Inc. 's 1. 04β — meaning GRDN is approximately 2314% more volatile than MCK relative to the S&P 500.

05

Which is growing faster — GRDN or MCK?

By revenue growth (latest reported year), Guardian Pharmacy Services, Inc.

(GRDN) is pulling ahead at 17. 9% versus 16. 2% for McKesson Corporation (MCK). On earnings-per-share growth, the picture is similar: Guardian Pharmacy Services, Inc. grew EPS 144. 1% year-over-year, compared to 14. 9% for McKesson Corporation. Over a 3-year CAGR, GRDN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — GRDN or MCK?

Guardian Pharmacy Services, Inc.

(GRDN) is the more profitable company, earning 3. 4% net margin versus 0. 9% for McKesson Corporation — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRDN leads at 6. 1% versus 1. 2% for MCK. At the gross margin level — before operating expenses — GRDN leads at 19. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is GRDN or MCK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Guardian Pharmacy Services, Inc. 's 1. 58x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, McKesson Corporation (MCK) trades at 19. 3x forward P/E versus 29. 6x for Guardian Pharmacy Services, Inc. — 10. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCK: 33. 8% to $1006. 50.

08

Which pays a better dividend — GRDN or MCK?

In this comparison, MCK (0.

4% yield) pays a dividend. GRDN does not pay a meaningful dividend and should not be held primarily for income.

09

Is GRDN or MCK better for a retirement portfolio?

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, GRDN: +126. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between GRDN and MCK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

GRDN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 12%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GRDN and MCK on the metrics below

Revenue Growth>
%
(GRDN: 2.2% · MCK: 6.0%)
P/E Ratio<
x
(GRDN: 46.5x · MCK: 29.2x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.